Corvex Total Cost of Revenue increased by 253.2% to $989.00K in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 74.4%, from $567.00K to $989.00K. This is a positive signal — lower values indicate better performance for this metric.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|
| Value | $1.22M | $380.00K | $845.00K | $567.00K | $642.00K | $362.00K | $280.00K | $989.00K |
| QoQ Change | — | -68.7% | +122.4% | -32.9% | +13.2% | -43.6% | -22.7% | +253.2% |
| YoY Change | — | — | — | — | -47.2% | -4.7% | -66.9% | +74.4% |
| Segment | Q1 '26 |
|---|---|
| Revenue Connected Devices And Services | $265.00K |
| Revenue AI Platform And Services | $247.00K |
| Total | — |
| Segment | Q1 '24 | Q1 '25 |
|---|---|---|
| Chief Operating Decision Maker | $1.16M | $641.00K |
| Total | $1.22M | $642.00K |
Chief Operating Decision Maker was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.